CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Shares of CG Oncology stock opened at $30.20 on Friday. The firm’s 50 day moving average is $32.44 and its 200 day moving average is $34.26. CG Oncology has a 1 year low of $25.77 and a 1 year ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday .The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 ...

CG Oncology, Inc. (CGON) closed the last trading session at $29.61, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

IRVINE, CA – CG Oncology, Inc. (CGON), a biotechnology firm specializing in biological products with a market capitalization of $2.06 billion, announced on Thursday, January 9, 2025, that it has ...

IRVINE, CA – CG Oncology, Inc. (CGON), a biotechnology firm specializing in biological products with a market capitalization of $2.06 billion, announced on Thursday, January 9, 2025, that it has ...

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and ...